MOESM2 of Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by 18F-FDG-PET is associated with the KRAS mutation status and prognosis

Additional file 2: Figure S1. The ROC curve analysis of the performance of 18F-FDG-PET parameters for predicting KRAS mutation status. (a) Maximum standardized uptake value (SUVmax), (b) metabolic tumor volume (MTV), and (c) total lesion glycolysis (TLG). Note the high area under the ROC curve (AUC), 95% confidence interval (CI), and cutoff value (red font). ROC receiver operating characteristic, AUC area under the curve

MOESM1 of Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by 18F-FDG-PET is associated with the KRAS mutation status and prognosis

Additional file 1: Table S1. Univariate and Multivariate analyses of prognostic factors for overall survival

Flow diagram showing the outcome of interferon therapy in patients with recurrent hepatitis C after living donor liver transplantation (LDLT) and indicating the classification of patients in this study.

<p>N, number of patients; VR, virological response; SVR, sustained virological response; NR, nonresponder.</p

Association of amino acid substitutions in the core region with virorogical response (VR) and sustained VR (SVR) in 40 patients infected with HCV genotype 1b: Univariate analysis.

<p>NOTE. Data are shown in number. P-values are calculated by Wald test for logistic regression analysis.</p><p>Arg, Arginine; Gln, glutamine; His, histidine; Leu, leucine; Met, methionine.</p

Predictive factors associated with sustained virological response (SVR): Multivariate analysis.

<p>HCV, hepatitis C virus; LT, liver transplantation.</p

Multivariate analysis of risk factors for SSIs in 72 pediatric living donor liver transplant recipients.

<p>SSI, surgical site infection; RR, relative risk; NHSN National Healthcare Safety Network. Bold type indicates statistically significant P values.</p><p>Multivariate analysis of risk factors for SSIs in 72 pediatric living donor liver transplant recipients.</p

Multivariate analysis of risk factors for SSIs in 129 adult living donor liver transplant recipients.

<p>SSI, surgical site infection; RR, relative risk; GRWR, graft-to-recipient body weight ratio. Bold type indicates statistically significant P values.</p><p>Multivariate analysis of risk factors for SSIs in 129 adult living donor liver transplant recipients.</p

Time-dependent changes tacrolimus concentration, Scr levels and urinary NGAL concentrations.

<p>The average ± SD values of tacrolimus trough concentrations, Scr levels and urinary NGAL concentrations in the liver transplant patients who experienced AKI during the period of postoperative day 1–5 (B, F, J), during the postoperative day 6–10 (C, G, K), after the postoperative day 11 (D, H, L) and AKI-free patients (A, E, I) are summarized. The cut-off values of urinary NGAL calculated from ROC analysis were 61.0 ng/mg creatinine (red dotted line).</p

Cumulative incidence of surgical site infection after living donor liver transplantation.

<p>This figure indicates the cumulative incidence of SSIs (A: adult recipients and B: pediatric recipients). P values (determined with a Log-rank test) are indicated in each graph. SSI, surgical site infection; LDLT living donor liver transplantation.</p

Patient characteristics.

<p>NOTE: The results are given as mean ± standard deviation. Statistical analysis was performed using the Mann-Whitney U test and Kruskal-Wallis test.</p><p><b>Abbreviations:</b> BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; MELD, Model for End-stage Liver Disease; Scr, serum creatinine; POD, postoperative day.</p><p>Patient characteristics.</p